Soluble endoglin, hypercholesterolemia and endothelial dysfunction

被引：52
|
作者：
Rathouska, Jana [1 ]
Jezkova, Katerina [1 ]
Nemeckova, Ivana [1 ]
Nachtigal, Petr [1 ]
机构：
[1] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Biol & Med Sci, Hradec Kralove 50005, Czech Republic
来源：
ATHEROSCLEROSIS | 2015年 / 243卷 / 02期
关键词：
Soluble endoglin; Hypercholesterolemia; Endothelial dysfunction; GROWTH-FACTOR-BETA; CELL-ADHESION MOLECULES; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; ENOS EXPRESSION; SERUM-LEVELS; CD105; ATHEROSCLEROSIS; RECEPTOR; RELEASE;
D O I：
10.1016/j.atherosclerosis.2015.10.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A soluble form of endoglin (sEng) is known to be an extracellular domain of the full-length membrane endoglin, which is elevated during various pathological conditions related to vascular endothelium. In the current review, we tried to summarize a possible role of soluble endoglin in cardiovascular pathologies, focusing on its relation to endothelial dysfunction and cholesterol levels. We discussed sEng as a proposed biomarker of cardiovascular disease progression, cardiovascular disease treatment and endothelial dysfunction. We also addressed a potential interaction of sEng with TGF-beta/eNOS or BMP-9 signaling. We suggest soluble endoglin levels to be monitored, because they reflect the progression/treatment efficacy of cardiovascular diseases related to endothelial dysfunction and hypercholesterolemia. A possible role of soluble endoglin as an inducer of endothelial dysfunction however remains to be elucidated. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：383 / 388
页数：6
相关论文
共 50 条
  • [1] Soluble endoglin, hypercholesterolemia and endothelial alteration
    Nachtigal, Petr
    Rathouska, Jana
    Jezkova, Katerina
    Fikrova, Petra
    Varejckova, Michala
    Dolezelova, Eva
    Nemeckova, Ivana
    [J]. ANGIOGENESIS, 2015, 18 (04) : 574 - 574
  • [2] Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta
    Vitverova, Barbora
    Blazickova, Katerina
    Najmanova, Iveta
    Vicen, Matej
    Hyspler, Radek
    Dolezelova, Eva
    Nemeckova, Ivana
    Tebbens, Jurjen Duintjer
    Bernabeu, Carmelo
    Pericacho, Miguel
    Nachtigal, Petr
    [J]. ATHEROSCLEROSIS, 2018, 271 : 15 - 25
  • [3] Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo
    Eissazadeh, Samira
    Mohammadi, Seyedehniloufar
    Faradonbeh, Fatemeh Alaei
    Rathouska, Jana Urbankova
    Nemeckova, Ivana
    Tripska, Katarina
    Vitverova, Barbora
    Dohnalkova, Ester
    Vasinova, Martina
    Fikrova, Petra
    Sa, Ivone Cristina Igreja
    Micuda, Stanislav
    Nachtigal, Petr
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (03):
  • [4] SOLUBLE ENDOGLIN PARTICIPATE ON THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION: OR NOT?
    Nachtigal, Petr
    Blazickova, Katerina
    Rathouska, Jana
    Najmanova, Iveta
    Vitverova, Barbora
    Vicen, Matej
    Dolezelova, Eva
    Nemeckova, Ivana
    Chlopicki, Stefan
    [J]. ATHEROSCLEROSIS, 2017, 263 : E135 - E135
  • [5] HIGH SOLUBLE ENDOGLIN LEVELS ACCOMPANIED BY MILD HYPERCHOLESTEROLEMIA ARE A RISK FACTOR FOR THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN MICE
    Vitverova, B.
    Blazickova, K.
    Najmanova, I.
    Vicen, M.
    Pericacho, M.
    Nachtigal, P.
    [J]. ATHEROSCLEROSIS, 2018, 275 : E124 - E124
  • [6] SOLUBLE ENDOGLIN COMBINED WITH HYPERCHOLESTEROLEMIA AFFECTS VASCULAR AND ENDOTHELIAL FUNCTION IN MICE
    Nachtigal, Petr
    Vitverova, Barbora
    Vicen, Matej
    Najmanova, Iveta
    Dolezelova, Eva
    Bernabeu, Carmelo
    Pericacho, Miguel
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 98 - 99
  • [7] THE ASSOCIATION OF SOLUBLE ENDOGLIN AND ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETES MELLITUS AND FAMILIAL HYPERCHOLESTEROLEMIA: IMPACT OF STATIN THERAPY
    Lasticova, M.
    Visek, J.
    Blaha, V.
    Blaha, M.
    Liptak, V.
    Nachtigal, P.
    [J]. ATHEROSCLEROSIS, 2022, 355 : E86 - E86
  • [8] EFFECT OF TREATMENT WITH STATINS ON PLASMA LEVELS OF SOLUBLE ENDOGLIN AND ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETES MELLITUS AND FAMILIAL HYPERCHOLESTEROLEMIA
    Lasticova, M.
    Visek, J.
    Blaha, V.
    Blaha, M.
    Lanska, M.
    Nachtigal, P.
    [J]. ATHEROSCLEROSIS, 2020, 315 : E110 - E110
  • [9] CRITICAL IMPACT OF ENDOGLIN BLOCKAGE IN ENDOTHELIAL DYSFUNCTION INDUCED BY HYPERCHOLESTEROLEMIA AND HYPERGLYCEMIA IN HUMAN AORTIC ENDOTHELIAL CELLS
    Tripska, K.
    Sa, I. C. Igreja
    Vicen, M.
    Eissazadeh, S.
    Svobodova, Z.
    Vitverova, B.
    Havelek, R.
    Theuer, C.
    Bernabeu, C.
    Nachtigal, P.
    [J]. ATHEROSCLEROSIS, 2022, 355 : E90 - E90
  • [10] SOLUBLE ENDOGLIN AND MARKERS OF ENDOTHELIAL FUNCTION/DYSFUNCTION IN MOUSE AORTA - A PILOT STUDY
    Jezkova, K.
    Rathouska, J.
    Nemeckova, I.
    Nachtigal, P.
    [J]. ATHEROSCLEROSIS, 2014, 235 (02) : E119 - E119
12345